Ayon

Gastroenterology

[Ayon @JoseAyonM]

@DocConTOC Justo como lo comentas, por ese rango dx tan limitado no es un criterio de calidad, toma más tiempo, mas efectos adversos propios el procedimiento y/o sedación; me imagino que este es la RCT con metanalisis que comentas, un must sin duda.

[Ayon @JoseAyonM]

@drkeithsiau The decision to do an endoscopy it’s made by pretest probability, having a clean DRE does not exclude an upper GI hemorrhage. Old habits die hard

[Alí S. Meza @AliSMV7]

The Fifth Mexican consensus on the diagnosis and treatment of Helicobacter pyloriinfection

🔺PCAB and more PCAB
🔺Doxycycline > Tetracycline ?

https://t.co/zAdSTb1pF7

[Alí S. Meza @AliSMV7]

Empirical Antifungal Therapy Improves Survival in patients with Acute-on-Chronic Liver Failure with Suspected Invasive Fungal Infections: A Pragmatic Randomised Trial

🔺Practice changer? As ID doctors, should we hide or show this data?

https://t.co/vbMOx15gIk

[Ayon @JoseAyonM]

📑First Latin American consensus on the treatment and prophylaxis of hepatic encephalopathy.

☑️LOLA for primary prophylaxis in variceal bleeding.
☑️WH III and IV: lactulose +rifaximin + LOLA
❌Probiotics and BCAA.
https://t.co/G1K2zzx34i

[Elliot Tapper @ebtapper]

Cirrhosis

[Ayon @JoseAyonM]

📑Point-of-care ultrasound (POCUS)–guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis

DOI: 10.1097/HEP.0000000000001524

[Ayon @JoseAyonM]

📑NEJM 2025- Noninvasive Assessment of Liver Fibrosis.

DOI: 10.1056/NEJMra2403308

[JAMA @JAMA_current]

💬 Editorial: The BICARICU-2 trial finds IV sodium bicarbonate may delay or reduce kidney replacement therapy in #criticallyill patients with severe #acidemia and #AKI, but its effect on mortality remains uncertain.

#LIVES2025 @ESICM

https://t.co/Lvf3wiQMP5

[Ayon @JoseAyonM]

📑Medical treatment of primary sclerosing cholangitis:
What have we learned and where are we going?

DOI:10.1097/HEP.0000000000001172

[Ayon @JoseAyonM]

📑Rifaximin Versus Low FODMAP Diet in Irritable Bowel Syndrome. Single blind, single center, RCT

Rfx and LFD effective in placebo control trials but there´s not a direct comparison
Outcome: Composite symptom improvement
☑️No difference between Rfx and lFD
https://t.co/e6EAFr9wRC

[Ayon @JoseAyonM]

📑BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update.

https://t.co/MYSUPwA53S

[Ayon @JoseAyonM]

📄Proton Pump Inhibitor Use in Patients with Cirrhosis and Its Association With Spontaneous Bacterial Peritonitis.

❌ There's no association between the use of PPI against no PPI as a risk factor of SBP.

https://t.co/Zr3tcu9wAI

[Ayon @JoseAyonM]

📑An evidence-based update on the diagnosis and management of Irritable Bowel Syndrome.

https://t.co/kleKoCFL2Z

[Ayon @JoseAyonM]

📑Evidence-based criteria for identifying at-risk individuals requiring liver disease screening.

🟢A way to predict LSM >12kPa based in two steps with risk factors (CLivD score, AST:ALT ratio, metabolic syndrome) and then a FIB-4 >1.3.

DOI: 10.1097/HC9.0000000000000679

[Ayon @JoseAyonM]

📑Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When.

https://t.co/fYX9V5tq8R

[Ayon @JoseAyonM]

📑The 2024 diagnostic criteria for primary sclerosing cholangitis.

-The past criteria were made only for Large Duct PSC.
-2024 diagnostic criteria are also designed for diagnosing small duct PSC and PSC recurrence following LTx.

https://t.co/PWvcfhZqBN

[Alí S. Meza @AliSMV7]

Helicobacter pylori’s secret resilience: coccoid forms, yeast havens, and outer membrane vesicle release for survival and spread

https://t.co/JKMe5ft0BT

[Ayon @JoseAyonM]

📑British Dietetic Association Guidelines for the Dietary Management of Chronic Constipation in Adults.

First guidelines specifically for the dietary management of chronic constipation. Evidence-based recommendations.

https://t.co/zK9V8xvZNj

[Ayon @JoseAyonM]

📑Hepatic encephalopathy: Part 2, inpatient management

doi:10.1136/flgastro-2025-103330